Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial

  • F. Penault-Llorca (Lead / Corresponding author)
  • , F. Dalenc
  • , S. Chabaud
  • , P. Cottu
  • , D. Allouache
  • , D. Cameron
  • , J. Grenier
  • , L. Venat Bouvet
  • , A. Jegannathen
  • , M. Campone
  • , M. Debled
  • , A. C. Hardy-Bessard
  • , S. Giacchetti
  • , P. Barthelemy
  • , L. Kaluzinski
  • , A. Mailliez
  • , M.-A. Mouret-Reynier
  • , E. Legouffe
  • , A. Cayre
  • , M. Martinez
    • C. Delbaldo, D. Mollon-Grange, E. J. Macaskill, M. Sephton, L. Stefani, B. Belgadi, M. Winter, H. Orfeuvre, M. Lacroix-Triki, H. Bonnefoi, J. Bliss, J.-L. Canon, J. Lemonnier, F. Andre, T. Bachelot

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)
109 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science